Wafik El-Deiry: The founders of the WIN Consortium had a bold vision for global impact in personalized cancer medicine
Wafik El-Deiry, Director of the Legorreta Cancer Center at Brown University, recently posted on LinkedIn:
“Terrific two-day international precision oncology event that was successful due to collaboration between the WIN Consortium in cancer personalized medicine and Burjeel Holdings.
The founders of the WIN Consortium (the late John Mendelsohn at MD Anderson Cancer Center who was Chair from 2010 until 2018 and the late Thomas Tursz at Gustav Roussy who was Vice Chair in 2010-2012, 2016-2018) had a bold vision for global impact in personalized cancer medicine through innovation and collaboration.
This vision holds true today in 2024 where the WIN Consortium is growing both in the US and throughout the world and building upon the remarkable successes over the past 15 years. Our Molecular Tumor Board, next-gen clinical trials and scientific meetings will drive progress as we grow and implement our vision.
We seek like-minded innovators and stakeholders to advance the frontiers of precision oncology to help patients with diversity and equity.
True collaboration (and not competition), open-mindedness, humility, and humanistic altruism is what will ultimately realize the impactful vision and advance the field. This can happen faster when academic institutions, big pharma, biotech, professional societies, patient advocacy organizations, governments and funding agencies work together towards a common goal to reduce the burden from cancer.
Precision care in oncology has been delivering on its promise and will continue to do so by purposeful implementation. Our predescessors showed feasibility and gave us the opportunity to go to the next level.”
Source: Wafik El-Deiry/LinkedIn